Introduction
Methods
Study design and participants
Statistical analyses
Results
Teriparatide (N = 680) | Risedronate (N = 680) | |
---|---|---|
Clinical vertebral | 7 | 24 |
Radius | 6 | 10 |
Hip | 2 | 5 |
Humerus | 4 | 2 |
Total number of MOF | 19 | 41 |
Teriparatide (n = 680) | Risedronate (n = 680) | HR (95% CI) | p value | |
---|---|---|---|---|
At 3 months | 4 (0.6%) | 4 (0.6%) | 0.62 (0.27, 1.41) | 0.251 |
At 6 months | 9 (1.4%) | 12 (1.8%) | 0.52 (0.27, 1.02) | 0.057 |
At 7 months | 9 (1.4%) | 17 (2.6%) | 0.50 (0.26, 0.93) | 0.030 |
At 8 months | 9 (1.4%) | 18 (2.8%) | 0.47 (0.26, 0.86) | 0.015 |
At 9 months | 9 (1.4%) | 19 (3.0%) | 0.45 (0.24, 0.81) | 0.008 |
At 12 months | 10 (1.5%) | 24 (3.8%) | 0.38 (0.20, 0.72) | 0.003 |
At 15 months | 12 (1.9%) | 28 (4.4%) | 0.32 (0.14, 0.71) | 0.005 |
At 18 months | 14 (2.2%) | 33 (5.3%) | 0.27 (0.10, 0.74) | 0.011 |
At 21 months | 15 (2.4%) | 36 (5.8%) | 0.23 (0.07, 0.79) | 0.020 |
At 24 months | 16 (2.6%) | 40 (6.4%) | 0.20 (0.05, 0.86) | 0.031 |
Teriparatide (n = 680) | Risedronate (n = 680) | HR (95% CI) | p value | |
---|---|---|---|---|
At 3 months | 6 (0.9%) | 7 (1.0%) | 0.70 (0.36, 1.37) | 0.299 |
At 6 months | 12 (1.8%) | 17 (2.6%) | 0.62 (0.37, 1.07) | 0.085 |
At 7 months | 12 (1.8%) | 23 (3.6%) | 0.60 (0.36, 0.99) | 0.046 |
At 8 months | 13 (2.0%) | 25 (3.9%) | 0.58 (0.36, 0.93) | 0.024 |
At 9 months | 14 (2.1%) | 26 (4.0%) | 0.56 (0.35, 0.88) | 0.012 |
At 12 months | 18 (2.8%) | 34 (5.3%) | 0.49 (0.31, 0.78) | 0.003 |
At 15 months | 22 (3.5%) | 39 (6.1%) | 0.44 (0.26, 0.76) | 0.003 |
At 18 months | 26 (4.1%) | 49 (7.8%) | 0.39 (0.20, 0.77) | 0.007 |
At 21 months | 27 (4.3%) | 55 (8.8%) | 0.35 (0.15, 0.81) | 0.014 |
At 24 months | 30 (4.8%) | 61 (9.8%) | 0.31 (0.11, 0.86) | 0.024 |